Consolidated Statement Of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Net cash flows from operating activities:
Net income	$ 7,946,000	$ 7,371,000	$ 3,944,000
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	5,633,000	4,960,000	3,937,000
Non-cash compensation	3,162,000	2,790,000	2,621,000
Deferred income taxes	1,227,000	1,767,000	(1,509,000)
Excess tax shortfall (benefit) from stock based compensation	143,000	445,000	(1,275,000)
Write-down of deferred preservation costs and inventories	288,000	270,000	2,093,000
Write-down of intangible asset	327,000	255,000	921,000
Other than temporary investment impairment	340,000		3,638,000
Acquired in-process research and development expense			3,513,000
Gain on valuation of derivative			(1,345,000)
Other non-cash adjustments to income	213,000	67,000	185,000
Changes in operating assets and liabilities:
Receivables	1,363,000	(2,230,000)	179,000
Deferred preservation costs and inventories	(1,598,000)	2,445,000	3,098,000
Prepaid expenses and other assets	(583,000)	(617,000)	(1,539,000)
Accounts payable, accrued expenses, and other liabilities	529,000	(772,000)	2,376,000
Net cash flows provided by operating activities	18,990,000	16,751,000	20,837,000
Net cash flows from investing activities:
Acquisition of PerClot intangible assets			(5,411,000)
Advances under notes receivable	(2,000,000)
Capital expenditures	(3,070,000)	(2,538,000)	(2,121,000)
Purchases of restricted securities and investments		(3,569,000)	(2,705,000)
Other	(810,000)	(547,000)	(497,000)
Net cash flows used in investing activities	(22,920,000)	(27,716,000)	(10,734,000)
Net cash flows from financing activities:
Cash dividends paid	(1,373,000)
Proceeds from financing insurance policies			1,179,000
Principal payments on capital leases and short-term notes payable		(31,000)	(1,537,000)
Proceeds from exercise of stock options and issuance of common stock	330,000	694,000	239,000
Repurchases of common stock	(3,529,000)	(3,064,000)	(5,877,000)
Excess tax (shortfall) benefit from stock based compensation	(143,000)	(445,000)	1,275,000
Net cash flows used in financing activities	(4,715,000)	(2,846,000)	(4,721,000)
(Decrease) increase in cash and cash equivalents	(8,645,000)	(13,811,000)	5,382,000
Effect of exchange rate changes on cash	(51,000)	19,000	(6,000)
Cash and cash equivalents, beginning of year	21,705,000	35,497,000	30,121,000
Cash and cash equivalents, end of year	13,009,000	21,705,000	35,497,000
Hemosphere [Member]
Net cash flows from investing activities:
Acquisition, net of cash acquired	(17,040,000)
Cardiogenesis [Member]
Net cash flows from investing activities:
Acquisition, net of cash acquired		$ (21,062,000)